SUMMARY The effect of bretylium tosylate (BT) was determined in 27 consecutive cases of resistant ventricular fibrillation (VF) encountered by a hospital cardiac arrest team. The VF was sustained and completely resistant to multiple injections of lidocaine, sequential DC shocks at 400 watt-sec and one or a combination of intravenous propranolol, diphenylhydantoin or procainamide. Following 30 min of sustained cardiac massage, BT (5 mg/kg i.v.) was administered. In 20 patients, VF was terminated within 9-12 min after DC shock. Eight of these patients failed to recover whUe 12 (44%) of all patients THE WIDESPREAD USE OF ANTIARRHYTHMIC AGENTS in coronary care units has succeeded in decreasing the incidence of ventricular fibrillation (VF) as a primary electrical disorder.1 It is estimated, however, that 30-50% of in-hospital deaths from ischemic heart disease occur suddenly either during the postcoronary care unit phase or on arrival in the emergency room. 2 An effective in-hospital mobile cardiac arrest team can serve as an extended CCU for these patients, and in fact, our experience since 1962 revealed that a significantly higher survival rate from resuscitation, presumably after primary VF antiarrhythmic drugs. This study indicates therefore that certain patients who develop sudden cardiac arrest in hospital have sustained and resistant primary ventricular fibrillation which is responsive to bretylium tosylate. As a pharmacological experiment, this study suffers from obvious unsteady state conditions and the previously administered antiarrhythmic agents which could conceivably have exerted a delayed effect. Nonetheless, there appeared to be a direct temporal relationship between the administration of bretylium and time of reversion (9-12 min). This time interval is in keeping with the known onset of the drug's action in the presence of other antiarrhythmic agents.5 ' Taylor et al. used bretylium in a controlled trial to evaluate its efficacy as a prophylactic agent in acute myocardial infarction.1" They found no significant decrease in the incidence of ventricular dysrhythmias and a 30% incidence of troublesome hypotensive episodes requiring withdrawal of the drug. The failure of bretylium to prevent ventricular ectopic activity as opposed to its effect on refractory VF may arise from its electrophysiologic properties. The drug's ability to raise the ventricular fibrillation threshold 160. has been documented'2 although the mechanism is not fully understood. The raised threshold may be related to the drug's hyperpolarizing effect by virtue of an early transient release of norepinephrine from adrenergic nerve terminals. '8, 1 More recent studies indicate that bretylium can prolong the action potential duration along the entire proximal conducting system while reducing the prolonged duration in cells from acutely infarcted regions."5 This uniform lengthening of refractoriness and hyperpolarization would favor a state of electrical uniformity throughout the tissue, thereby reducing the opportunity for re-entrant circuits to develop. A 20% decrease in systolic blood pressure occurred in three-quarters of the survivors while on 48 hour maintenance bretylium. While other factors may have contributed to the variations in systolic pressures following at least 30 min of cardiopulmonary resuscitation, the fact that all nine patients with hypotension demonstrated an improvement in blood pressure on discontinuation of bretylium implies that the drug was partly responsible for the hypotensive state during the 48 hour postresuscitation period. In only three of the 12 survivors were vasopressor agents and/or fluid replacement thought necessary to control the blood pressure during maintenance therapy. We do not feel that hypotension is a serious enough side effect to preclude the use of maintenance bretylium following resuscitation. Although this study does not indicate whether maintenance therapy is indeed necessary, several patients demonstrated short salvos of ventricular ectopic beats when the interval between the injections was prolonged from eight to 12 hours. One patient could not be weaned from bretylium at any time during his 5 week hospital course without developing serious and malignant ventricular ectopic activity. He was subsequently discharged on oral bretylium (Darenthin) 200 mg t.i.d.
Recent reports suggest that bretylium may increase infarct size as a result of its inotropic properties.'" There is no clinical evidence to date which substantiates this theory and the animal experiments attesting to the drug's effect on increased infarct size must be weighed against those experiments showing augmented coronary flow and possible inhibition of coronary vascular spasm.'7 These hemodynamic properties should in no way detract from its effect as an antiarrhythmic agent for resistant ventricular fibrillation. Until such time as its clinical effect in ischemic heart disease becomes firmly established, it would probably be best to confine its use to resistant and/or malignant ventricular arrhythmias.
The geographic distribution of hospitalized patients suffering sudden cardiac arrest with resistant VF coincides with the observed distribution of cardiac arrests in general.2' Primary electrical disorders, therefore, still occur in hospital and this study indicates that following the failure { I of conventional resuscitative efforts, many of these patients can be saved with the administration of intravenous bretylium tosylate. This is not to say that bretylium tosylate is either superior or should be used in preference to other antiarrhythmic agents. As Koch-Weser has indicated, it may very well be that equal numbers of patients unresponsive to bretylium may derive a similar benefit from lidocaine if the sequence of the antiarrhythmic agents were reversed.7 This thesis however, has not been proven and, judging from this series of patients, would merit careful scrutiny and further clinical testing.
